Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Feb 01, 2008 (Vol. 28, No. 3)

Latest Trends and News

URL:www.medicineandbiotech.com
  • Well organized, well written, topical
  • None
MedicineandBiotech has important news on a timely subject. The site’s name clearly defines its content and it dazzles with topical information. Biotechnology, of course, is the gateway through which almost all modern medicines are arriving. Covering such a rapidly changing subject is a challenge, but MedicineandBiotech meets it nicely. Headline stories on the site at press time included FDA approval for the first oral HIV integrase inhibitor, a policy report on synthetic genomics (by Craig Venter), hope for an ovarian cancer vaccine, and article on increasing supplies for a pandemic influenza vaccine. The site contains a nicely categorized collection of topics (genomics, stem cells, news, nanotech, science education, and much more). There’s an awful lot to like here and I couldn’t find a single shortcoming. I recommend it to you highly.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »